{"filing":{"accession_number":"0001829126-26-007666","cik":"0002079364","ticker":null,"company_name":"Veraxa Biotech AG","form":"6-K","filing_date":"2026-07-20","report_date":null,"primary_document":"veraxabiotechag_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079364/000182912626007666/veraxabiotechag_6k.htm"},"events":[{"id":18769,"run_id":16885,"accession_number":"0001829126-26-007666","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"VERAXA announced receipt of Scientific Advice from the German regulatory authority (Paul-Ehrlich-Institute) supporting the biological rationale and proposed development approach for its BiTAC-TCE technology platform. This is a material regulatory milestone that de-risks the development path for the company's most-advanced program and provides clarity on the regulatory pathway forward. While not a discrete event type like exec_appointment or debt_issuance, this regulatory validation is a significant operational/strategic development that would affect a reasonable investor's assessment of the company's progress toward clinical development.","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-20","form":"6-K","submitted_at":null,"items":[{"id":17679,"accession_number":"0001829126-26-007666","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"VERAXA announced receipt of Scientific Advice from the German regulatory authority (Paul-Ehrlich-Institute) supporting the biological rationale and proposed development approach for its BiTAC-TCE technology platform. This is a material regulatory milestone that de-risks the development path for the company's most-advanced program and provides clarity on the regulatory pathway forward. While not a discrete event type like exec_appointment or debt_issuance, this regulatory validation is a significant operational/strategic development that would affect a reasonable investor's assessment of the company's progress toward clinical development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:06:38.514832+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17679,"accession_number":"0001829126-26-007666","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"VERAXA announced receipt of Scientific Advice from the German regulatory authority (Paul-Ehrlich-Institute) supporting the biological rationale and proposed development approach for its BiTAC-TCE technology platform. This is a material regulatory milestone that de-risks the development path for the company's most-advanced program and provides clarity on the regulatory pathway forward. While not a discrete event type like exec_appointment or debt_issuance, this regulatory validation is a significant operational/strategic development that would affect a reasonable investor's assessment of the company's progress toward clinical development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:06:38.514832+00:00","company_name":"Veraxa Biotech AG","ticker":null,"filing_date":"2026-07-20"}]}